Peter Parker

Peter joined the Board in January 2021. He is also Chair of the Institute’s Science and Impact Advisory Committee (SIAC).

Peter Parker trained as a Biochemist at Oxford. He moved to Dundee to study protein kinases and then moved into oncology at the Imperial Cancer Research Fund (ICRF) in London, subsequently moving as a founder member to the Ludwig Institute for Cancer Research at UCL. He later returned as a Principal Scientist to the ICRF before moving to the newly founded Francis Crick Institute in 2015. Peter has held a joint appointment with King’s College London since 2006 where he was Head of the Cancer Division until 2017; he is currently Director of the Cancer Research UK King’s Health Partners Centre at KCL.

Peter has served on committees for many granting organisations in particular for CRUK and the MRC. He is also a member of various Advisory Boards for academic and commercial concerns.

Peter is a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences and a Member of the European Molecular Biology Organisation.

With a strong oncology focus, Peter’s longstanding research interests concern protein kinases, biomarkers and targeted interventions; Peter has co-founded three companies in these research domains.